Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Alzheimer’s Research & Therapy

the AIBL Research Group¹  Samantha C. Burnham²  Stephanie R. Rainey-Smith³  Larry Ward⁴  James D. Doecke⁴  Ralph N. Martins⁵  Monika Widmann⁶  Ekaterina Manuilova⁶  Victor L. Villemagne⁷  Steven Collins⁷  Qiao-Xin Li⁷  Christopher J. Fowler⁷  Colin L. Masters⁷ 

[1] ;Australian E-Health Research Centre, CSIRO;Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University;Cooperative Research Council for Mental Health;Department of Biomedical Sciences, Macquarie University;Roche Diagnostics GmbH;The Florey Institute of Neuroscience and Mental Health, The University of Melbourne;

关键词: Alzheimer’s disease;    Beta-amyloid;    Cerebrospinal fluid;    Concordance PET;    Tau;   

DOI  :  10.1186/s13195-020-00595-5

来源: DOAJ

【 摘 要 】

Abstract Background β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1–42) (Aβ42), Aβ (1–40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic—area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.

【 授权许可】

Unknown